FDA Inspection 1243433 — TriRx Segre
The FDA completed an inspection of TriRx Segre on Jan 13, 2022 in Segre-En-Anjou Bleu. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Veterinary.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Jan 13, 2022
- Fiscal Year
- 2022
- Product Type
- Veterinary
- Project Area
- Monitoring of Marketed Animal Drugs, Feed, and Devices
- Location
- Segre-En-Anjou Bleu (France)
Additional Details
Mutual Recognition Agreement (MRA)